Anxiety: When to See a Doctor and When to Worry

The Line Between Normal Worry and Clinical Anxiety

Everyone worries before a job interview or a medical test. That kind of short-lived tension serves a protective function, sharpening focus when stakes are high. Clinical anxiety is different in duration, intensity, and the degree to which it resists rational reassurance.

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) defines generalized anxiety disorder (GAD) as excessive anxiety and worry occurring more days than not for at least six months, accompanied by three or more symptoms: restlessness, fatigue, difficulty concentrating, irritability, muscle tension, or sleep disturbance 1. The key qualifier is "difficult to control." If you can redirect your attention and the worry fades, the episode is likely situational. If the worry returns within minutes, shifts to a new target, and resists logic, that pattern fits the clinical definition.

Data from the National Comorbidity Survey Replication (NCS-R, N=9,282) found a 5.7% twelve-month prevalence and a 6.8% lifetime prevalence of GAD among U.S. adults 2. Women are diagnosed at roughly twice the rate of men. The disorder rarely appears in isolation. About 60% of individuals with GAD also meet criteria for comorbid major depressive disorder, and nearly 50% have a co-occurring second anxiety disorder 2.

Short answer: if the worry has lasted weeks, feels uncontrollable, and has started affecting sleep, appetite, or daily function, it has crossed the line.

What Causes Anxiety?

Anxiety disorders arise from a convergence of genetic predisposition, neurobiological changes, environmental stressors, and learned behavior patterns. No single factor is sufficient on its own.

Twin studies estimate the heritability of GAD at 30% to 40%, with shared genetic architecture between GAD and major depression 3. At the neurotransmitter level, dysregulation of serotonin, norepinephrine, and gamma-aminobutyric acid (GABA) pathways has been consistently implicated. Functional neuroimaging studies show hyperactivity in the amygdala and reduced prefrontal cortical regulation in patients with anxiety disorders compared to healthy controls 4.

Environmental triggers include early-life adversity, chronic medical illness, substance use (particularly stimulants and alcohol withdrawal), and sustained psychosocial stress such as financial insecurity or caregiving burden. Thyroid dysfunction, cardiac arrhythmias, and medication side effects can mimic or worsen anxiety, which is why a medical workup matters before assuming the cause is purely psychological.

Dr. Murray Stein, a psychiatrist at the University of California San Diego and editor of multiple anxiety disorder guidelines, has written: "Anxiety disorders are among the most common, most impairing, and most costly of all mental disorders, yet they remain undertreated relative to their burden" 5.

The World Health Organization reported that anxiety disorders affected an estimated 301 million people globally in 2019, making them the most prevalent class of mental disorders worldwide 6.

Red Flags: When Anxiety Needs Medical Attention

The threshold for seeking care is lower than most people assume. You do not need to be in crisis. A persistent shift in baseline functioning is reason enough.

Seek evaluation if any of the following apply:

• Worry or dread persists most days for four weeks or longer without a clear external cause.
• Physical symptoms (chest tightness, gastrointestinal distress, headaches, muscle tension) recur without an identifiable medical explanation.
• Sleep is disrupted on three or more nights per week.
• You have begun avoiding situations, places, or social interactions that you previously handled without difficulty.
• Concentration impairment is affecting work performance, academic output, or driving safety.
• You are using alcohol, benzodiazepines, or cannabis to manage the feeling.
• You experience panic attacks (sudden surges of intense fear with palpitations, shortness of breath, dizziness, or derealization).

Seek emergency care immediately if anxiety co-occurs with suicidal ideation, self-harm urges, or a dissociative episode that impairs awareness of your surroundings.

A useful self-check is the "interference test." Ask yourself: has anxiety changed what I do, where I go, or how I relate to people I care about? One "yes" is enough to justify a visit. The goal of early evaluation is not to label you with a disorder. It is to rule out medical mimics (hyperthyroidism, cardiac arrhythmia, pheochromocytoma) and to start treatment before avoidance behaviors become entrenched.

How Anxiety Is Diagnosed

Diagnosis begins with a structured clinical interview and a validated self-report questionnaire. The GAD-7 (Generalized Anxiety Disorder 7-item scale) is the most widely used screening tool in primary care worldwide.

Developed and validated by Spitzer, Kroenke, Williams, and Löwe in a primary care sample of 2,740 patients, the GAD-7 demonstrated a sensitivity of 89% and specificity of 82% at a cutoff score of 10 for identifying generalized anxiety disorder 7. Scores of 5, 10, and 15 represent mild, moderate, and severe anxiety, respectively. The questionnaire takes under three minutes to complete.

Your clinician will also take a thorough history. Expect questions about onset, duration, triggers, family psychiatric history, substance use, caffeine intake, and current medications. A physical exam and basic laboratory panel (thyroid-stimulating hormone, complete blood count, comprehensive metabolic panel) help exclude medical causes that present with anxiety-like symptoms.

The American Psychiatric Association's 2023 Clinical Practice Guideline for Anxiety and Related Disorders states: "Screening with a validated instrument such as the GAD-7, followed by a comprehensive clinical assessment, is recommended as the standard approach to identifying anxiety disorders in both primary care and specialty settings" 8.

If panic disorder, social anxiety disorder, or obsessive-compulsive features are suspected, additional instruments (Panic Disorder Severity Scale, Liebowitz Social Anxiety Scale) may be administered. Referral to a psychiatrist or psychologist is appropriate when the presentation is complex, comorbid, or treatment-resistant.

First-Line Treatments That Work

Treatment for anxiety disorders falls into two evidence-based categories: psychotherapy and pharmacotherapy. For moderate to severe GAD, guidelines recommend offering both.

Cognitive-Behavioral Therapy (CBT)

CBT is the most rigorously studied psychotherapy for anxiety. A Cochrane systematic review and meta-analysis (31 trials, N=3,293) found that CBT produced significantly greater improvement in anxiety symptoms compared with waitlist, treatment-as-usual, or placebo controls, with a standardized mean difference of -1.0 (95% CI -1.24 to -0.77) 9. The number needed to treat to achieve one additional responder was approximately 2.5. That is a strong effect. Therapy typically runs 12 to 16 weekly sessions and focuses on identifying cognitive distortions, restructuring catastrophic thought patterns, and graded exposure to feared situations.

SSRI and SNRI Medications

Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are first-line pharmacotherapy for GAD, panic disorder, and social anxiety disorder. Sertraline, escitalopram, paroxetine, venlafaxine extended-release, and duloxetine all carry FDA approval for one or more anxiety indications 10.

A network meta-analysis of 89 randomized controlled trials (N=25,441) published in The Lancet Psychiatry ranked duloxetine, pregabalin, venlafaxine, and escitalopram among the most effective agents for GAD based on combined efficacy and acceptability 11. Onset of therapeutic effect typically occurs at two to four weeks. Full response may take six to eight weeks, which is why premature discontinuation is one of the most common reasons for treatment failure.

Starting doses should be low. Sertraline at 25 mg daily for the first week, then increasing to 50 mg, reduces the transient jitteriness that SSRIs can cause in anxious patients. Your prescriber should schedule a follow-up within two to four weeks of initiation.

Other Options

Buspirone, a 5-HT1A partial agonist, is FDA-approved for GAD and may be preferred when sedation or sexual side effects from SSRIs are a concern. It requires consistent daily dosing and takes two to four weeks to reach efficacy. Benzodiazepines (lorazepam, clonazepam) provide rapid relief but carry dependence risk and are not recommended for long-term use by the APA guideline 8. Hydroxyzine is sometimes used for short-term or as-needed anxiolysis, though evidence is limited to small trials.

What Happens at Your First Appointment

Knowing the sequence of a first anxiety evaluation can reduce the anticipatory dread that keeps many people from scheduling one.

The visit typically lasts 30 to 60 minutes. You will complete intake paperwork that includes the GAD-7 and often the PHQ-9 (a depression screener), because the two conditions overlap so frequently. The clinician will ask open-ended questions about when the anxiety started, what makes it worse, and what you have already tried. Be direct about alcohol and substance use. Clinicians need accurate information to prescribe safely, and the conversation is confidential.

A physical exam focused on thyroid palpation, heart rate, blood pressure, and tremor assessment follows. Lab orders (TSH, CBC, CMP) are routine. If the results are normal and the clinical picture fits an anxiety disorder, you and your clinician will discuss treatment options and set measurable goals. A reasonable initial target is a 50% reduction in GAD-7 score within eight to twelve weeks.

Plan to bring a list of all medications, supplements, and recreational substances you use. Bring a written note about your symptoms if you worry you will forget details. Ask about the expected timeline for improvement, side effects to watch for, and when to call between visits. The first appointment is a diagnostic session, not a commitment to any specific treatment.

Lifestyle Interventions With Supporting Evidence

Pharmacotherapy and psychotherapy produce the strongest effect sizes, but several lifestyle modifications have randomized trial support and can be used alongside standard treatment.

Aerobic exercise at moderate intensity (150 minutes per week) reduced anxiety symptoms with an effect size comparable to low-dose SSRIs in a meta-analysis of 13 RCTs (N=1,039) 12. Walking, cycling, and swimming all qualify. The anxiolytic effect appears within the first two weeks of consistent activity.

Caffeine reduction matters. Caffeine doses above 400 mg daily (roughly four 8-oz cups of coffee) can provoke or amplify anxiety symptoms, particularly in individuals with panic disorder. Gradual tapering over seven to ten days prevents withdrawal headaches.

Sleep hygiene interventions (consistent wake time, no screens 60 minutes before bed, cool and dark bedroom) support anxiety recovery because insomnia and anxiety share bidirectional causality. A study of 3,755 adults found that poor sleep quality predicted incident anxiety at one-year follow-up independently of baseline depression 13.

Mindfulness-based stress reduction (MBSR) showed non-inferiority to escitalopram for GAD in a randomized trial (N=276) published in JAMA Psychiatry, with a mean reduction of 6.4 points on the Clinical Global Impression severity scale in the MBSR group versus 5.8 in the escitalopram group over eight weeks 14.

Anxiety in Specific Populations

Anxiety does not present identically across all groups. Recognition of population-specific patterns improves diagnostic accuracy.

Older adults. GAD is the most common anxiety disorder in people over 65, yet it is frequently mistaken for cognitive decline or dismissed as a normal response to aging. Somatic complaints (dizziness, gastrointestinal upset, fatigue) often dominate the clinical picture rather than the psychological language of "worry." SSRIs remain first-line, but starting doses should be halved, and benzodiazepines carry increased fall and fracture risk in this group 15.

Postpartum. Perinatal anxiety disorders affect approximately 15% of pregnant and postpartum individuals, a rate comparable to perinatal depression. Screening with the GAD-7 at obstetric visits is recommended by ACOG 16. Sertraline is generally compatible with breastfeeding.

Adolescents. The median age of onset for anxiety disorders is 11 years. CBT is the preferred first-line treatment for youth. The CAMS trial (N=488) demonstrated that combination CBT plus sertraline achieved an 80.7% response rate at 12 weeks, compared with 59.7% for CBT alone and 54.9% for sertraline alone 17.

Patients taking GLP-1 receptor agonists or testosterone replacement therapy should be aware that hormonal shifts can influence anxiety. Testosterone deficiency is associated with increased anxiety symptom burden, and normalization of testosterone levels in hypogonadal men has been linked to mood improvement in several small RCTs 18.

When Treatment Is Not Working

If symptoms have not improved after eight weeks of an adequate SSRI dose (e.g., sertraline 150 mg/day), the next steps include confirming medication adherence, reassessing the diagnosis, and considering augmentation or switch strategies.

Switching within the SSRI/SNRI class is reasonable. Moving from sertraline to escitalopram or to venlafaxine XR is a common clinical sequence. Augmentation with buspirone or pregabalin has moderate evidence. Adding CBT to pharmacotherapy when either alone has been insufficient is strongly supported by the APA guideline 8.

Reassess for comorbidities. Untreated ADHD, PTSD, alcohol use disorder, and obstructive sleep apnea can all perpetuate anxiety despite adequate primary treatment. A psychiatric referral is appropriate at this stage if one has not already occurred.

The GAD-7 should be repeated at each follow-up visit to track response objectively. A drop of five or more points from baseline indicates clinically meaningful improvement. Treatment duration for a first episode of GAD should extend at least 12 months after achieving remission to reduce relapse risk, which exceeds 50% if medication is stopped before that mark 11.